|BioDelivery Dips on Lawsuit News|
|By Vinny Cassano|
|Wednesday, 19 January 2011 12:59|
Shares of BioDelivery Sciences (NASDAQ:BDSI) took a 10% haircut on Tuesday and suffered another 8% drop today, after the company announced that a patent infringement filed by MonoSol Rx, LLC against BioDelivery, ONSOLIS partner MEDA and Aveva Drug Delivery Systems, Inc this past November has been amended to include a 'false marketing' charge.
The potential of BioDelivery lies in the future of ONSOLIS sales both in the US and abroad, and even moreso in the pipeline products that are being developed using the BEMA drug delivery technology.
The lawsuit is a factor to take into consideration, most certainly, but it's not likely, in my opinion, that the suit will amount to much other than a slap on the wrist, with a modest settlement sum or royalty rate being awarded to MonoSol as an outcome.
I'm more interested in the development of BioDelivery's pipeline than this lawsuit, at least for the time being, but I'm always a fan of selling some trading shares into any significant spikes just to cover all bases.
BDSI is no different. Worth watching.Vinny also authors the popular stock investing blog VFC's Stock House.